Published Online
on July 30, 2009

A more recent version of this article appeared on September 1, 2009

This Article Full Text (PDF) All Versions of this Article: 40/9/3161    most recent STROKEAHA.109.559062v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Strauss, M. H. Articles by Hall, A. PubMed PubMed Citation Articles by Strauss, M. H. Articles by Hall, A. Related Collections Secondary prevention ACE/Angiotension receptors Other Stroke Treatment - Medical

Submitted on May 29, 2009
Accepted on May 29, 2009

Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings. No

Martin H. Strauss MD, FRCP(C), FACC^* and Alistair Hall MB, ChB, PhD, FRCP(UK)

From the Clinical Cardiology, C-NET Research Group, LIGHT (Leeds Institute for Genetics Health and Therapeutics), Faculty of Medicine, University of Leeds, UK.

^* To whom correspondence should be addressed. E-mail: Dr.Marty{at}bellnet.ca.

Key words: prevention • receptors • ARB • stroke • renin angiotensin system

This article has been cited by other articles:

				M. H. Strauss and A. S. Hall Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study Eur. Heart J., November 27, 2009; (2009) ehp515v1. [Full Text] [PDF]